Research
Education
Sign In
EN
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Turkish
JA - Japanese
T Cell Engineering,
Division of Hematology
Elizabeth L. Siegler has not added Biography.
If you are Elizabeth L. Siegler and would like to personalize this page please email our Author Liaison for assistance.
ERK Activation in CAR T Cells Is Amplified by CD28-Mediated Increase in CD3ζ Phosphorylation.
iScience Apr, 2020 | Pubmed ID: 32325413
Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies.
Frontiers in immunology , 2020 | Pubmed ID: 32983132
A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
Neurologic clinics 11, 2020 | Pubmed ID: 33040871
Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia.
Molecular therapy : the journal of the American Society of Gene Therapy 04, 2021 | Pubmed ID: 33388419
CART Cell Toxicities: New Insight into Mechanisms and Management.
Clinical hematology international Dec, 2020 | Pubmed ID: 33409484
CRISPR Takes the Front Seat in CART-Cell Development.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy Mar, 2021 | Pubmed ID: 33638865
Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies.
Leukemia & lymphoma 09, 2021 | Pubmed ID: 33682608
CART cell imaging: Paving the way for success in CART cell therapy.
Molecular therapy oncolytics Mar, 2021 | Pubmed ID: 33816781
Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity.
Cancer immunology research 09, 2021 | Pubmed ID: 34244299
Targeting Cancer-Associated Fibroblasts in the Bone Marrow Prevents Resistance to CART-Cell Therapy in Multiple Myeloma.
Blood Jan, 2022 | Pubmed ID: 35090171
Challenges of CAR T-cell Therapy in CLL: Lessons Learned.
Experimental hematology Feb, 2022 | Pubmed ID: 35150777
Mayo Clinic
Mayo Clinic, Rochester
Reona Sakemura1,2,
Michelle J. Cox1,2,
Aditya Bansal3,
Claudia Manriquez Roman1,2,4,5,
Mehrdad Hefazi1,2,
Cynthia J. Vernon3,
Dianna L. Glynn3,
Mukesh K. Pandey3,
Timothy R. DeGrado3,
Elizabeth L. Siegler1,2,
Saad S. Kenderian1,2,5,6
1T Cell Engineering, Mayo Clinic,
2Division of Hematology, Mayo Clinic,
3Department of Radiology, Mayo Clinic,
4Regenerative Sciences PhD, Mayo Clinic,
5Department of Molecular Medicine, Mayo Clinic,
6Department of Immunology, Mayo Clinic
Claudia Manriquez Roman1,2,3,4,5,
R. Leo Sakemura1,2,
Brooke L. Kimball1,2,
Fang Jin6,
Roman H. Khadka6,
Mohamad M. Adada1,2,
Aaron J. Johnson6,
Saad S. Kenderian1,2,6
1T Cell Engineering Laboratory, Mayo Clinic, Rochester,
2Division of Hematology, Mayo Clinic, Rochester,
3Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester,
4Department of Molecular Medicine, Mayo Clinic, Rochester,
5Regenerative Sciences PhD Program, Mayo Clinic, Rochester,
6Department of Immunology, Mayo Clinic, Rochester
Privacy
Terms of Use
Policies
Contact Us
Recommend to library
JoVE NEWSLETTERS
JoVE Journal
Methods Collections
JoVE Encyclopedia of Experiments
Archive
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Faculty Resource Center
Authors
Librarians
Access
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved